Literature DB >> 34212840

Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021.

Cécile Tran Kiem1,2, Alessio Andronico2, Paolo Bosetti2, Juliette Paireau3,2, Lise Alter4, Pierre-Yves Boëlle5, Arnaud Fontanet6,7, Daniel Lévy-Bruhl3, Simon Cauchemez2.   

Abstract

Thrombosis with thrombocytopenia (TTS) has been identified as a rare adverse event following COVID-19 vaccination with Vaxzevria. We modelled the benefits and risks of Vaxzevria distribution from May to September 2021 in metropolitan France where other vaccines are available, considering French hospitalisation data and European data on TTS. Across different scenarios, benefits of Vaxzevria distribution in people 55 years and older exceeded the risk of death from COVID-19. In young adults, risks were at least of similar magnitude as benefits.

Entities:  

Keywords:  AstraZeneca; SARS-CoV-2; Vaxzevria; benefit-risk balance; thrombosis; vaccine

Year:  2021        PMID： 34212840     DOI： 10.2807/1560-7917.ES.2021.26.26.2100533

Source DB:  PubMed          Journal:  Euro Surveill        ISSN： 1025-496X


  5 in total

1.  Debate on mandatory COVID-19 vaccination.

Authors:  F K Cheng
Journal:  Ethics Med Public Health       Date:  2022-01-24

2.  COVID-19 Vaccines in Indonesia: Knowledge, Attitudes, and Acceptance Among Dental Professionals.

Authors:  Citra Fragrantia Theodorea; Armelia Sari Widyarman; Iwan Dewanto; Tri Erri Astoeti
Journal:  Front Med (Lausanne)       Date:  2021-12-21

Review 3.  Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn.

Authors:  Mehdi Shahgolzari; Afagh Yavari; Yaser Arjeini; Seyed Mohammad Miri; Amirhossein Darabi; Amir Sasan Mozaffari Nejad; Mohsen Keshavarz
Journal:  Gene Rep       Date:  2021-11-05

Review 4.  COVID-19, Vaccines, and Thrombotic Events: A Narrative Review.

Authors:  Maurizio G Abrignani; Adriano Murrone; Leonardo De Luca; Loris Roncon; Andrea Di Lenarda; Serafina Valente; Pasquale Caldarola; Carmine Riccio; Fabrizio Oliva; Michele M Gulizia; Domenico Gabrielli; Furio Colivicchi
Journal:  J Clin Med       Date:  2022-02-11       Impact factor: 4.241

Review 5.  Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines.

Authors:  Narasimha M Beeraka; Olga A Sukocheva; Elena Lukina; Junqi Liu; Ruitai Fan
Journal:  Rev Med Virol       Date:  2022-04-13       Impact factor: 11.043
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.